OTC · NNRX
Nutranomics, Inc.
$0.00$0.00 (0.0%)
Nutranomics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
Loading market information…
OTC · ENDV · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Endonovo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Endonovo Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Nutranomics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00+$0.00 (+30.0%)
CNBX Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.43% below the high.
$0.00$0.00 (0.0%)
Baseline Productions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.00$0.00 (0.0%)
Medical Imaging Corp.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$0.00$0.00 (0.0%)
West Island Brands Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Itoco Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
Amarantus BioScience Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
Affymax, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.08% below the high.
